Purpose: To determine the clinical characteristics of the subpopulation of patients not included in clinical trials, their outcome, and the reasons for their ineligibility and non-participation.
Introduction
Treatment modalities in medicine must be evaluated and compared by means of clinical trials. However, the highly selected groups of patients included in trials represent only a fraction of the eligible patients; in turn, the group of eligible patients is a small subgroup of the physician's target population, which itself is a sample of the overall population of patients [1] . Thus, it may be erroneous to relate the data obtained from such poorly representative samples to the entire affected population.
Firstly, the group of patients included in trials may differ from the eligible population as a whole because of patient and physician selection biases [2] . For instance, discrepancies between the results of different clinical trials, as well as frequent failure to confirm the results of small trials in large multicenter trials, may be due to such biases. Previous studies have shown that selection biases are more likely to occur when the proportion of included patients as a percentage of eligible patients is low [2] [3] [4] .
Secondly, the study population may differ from the general population because of restrictive eligibility criteria, even in the absence of selection bias [4] . Restricting the eligible population may limit the applicability of the results and the ability to generalize the data from a given study to the relevant patient population. Survival, response and tolerance to treatment are commonly used endpoints in clinical oncology protocols, and are clearly related to the initial state of the patient. Advanced age is one of the disqualifying criteria in many lung cancer clinical trials, because of a presumed higher risk of toxicity, although this may be irrelevant [5] . Since the prognostic impact of age on treatment results has been shown in some studies [6] , one may expect different treatment results between eligible and ineligible patients. Therefore, eligibility criteria may affect treatment results, and are of critical importance in the design of clinical trials. However, very few studies have been conducted to determine the proportion of ineligible patients and the reasons for their ineligibility [2, 4, 7] , as well as the prognosis of ineligible patients as compared to eligible patients.
The aims of the present retrospective study were: (1) to determine what fraction of patients referred to our center for treatment of small-cell lung cancer (SCLC) were not enrolled in one of the three successive clinical trials that we completed during a five-year period [8] [9] [10] [11] ; (2) to determine the reasons for ineligibility and/or nonparticipation; (3) to characterize the clinical features of the patients not included in the trials; (4) to compare their clinical characteristics as well as treatment issues to those of patients included in clinical trials. were included in one of the three clinical trials in which our group participated during this period ( Table 1) . Most of the selection criteria for these three trials were identical and included pathology proof of SCLC, absence of previously diagnosed cancer (except for basocellular carcinoma of the skin or in situ carcinoma of the uterine cervix), no prior chemotherapy, contraindication to surgical resection, absence of cardiac contraindication to the use of anthracyclines, and feasiblity of long-term follow-up. Some selection criteria varied from one trial to another and are listed in Table 2 . All three trials were approved by a local ethics committee. Based on the assessment of the above-listed selection criteria, 57 patients were not included in the on-going trials. They were registered, managed and treated individually, and strictly followed. We retrospectively studied the initial clinical characteristics of this subpopulation of excluded patients, the reasons for their ineligibility and non-participation, the staging procedures they underwent, the treatments they received, and their outcomes. 
Patients and methods

Comparative analysis of included and non-included patients
Because of the above-mentioned differences in selection criteria from one trial to another, and because detailed data on patients included in the AR 88/01 trial were not available, we chose to perform the comparative analysis only between patients included (// = 73) and those not included (n = 37) in the GLOT PC 86/01 trial. In order to facilitate the interpretation of the comparative results, the procedures of the GLOT PC 86/01 trial are summarized below.
Pre-lreatment staging in the GLOT PC 86/01 study
Staging procedures for patients selected for the GLOT PC 86/01 phase II study included a chest X-ray, assessment of blood cell counts, liver function tests (aspartate and alanine amino-transferases, gamma glutamyl-transferase, bilirubin, alkaline phosphatase, prothrombin time), serum creatinine levels, a fiberoptic bronchoscopy with multiple biopsies and cytology of bronchial aspirates, a unilateral iliac crest bone marrow aspiration and biopsy, an abdominal ultrasonography, brain and thoracic (and optionally abdominal) CT scans and a radionucleide bone scan. Limited disease was defined as a disease encompassable in the initial large radiation field, including homolateral pleural effusion, pericardial involvement and/or controlateral hilar mass. Extensive disease was defined on the basis of any evidence of extrathoracic spread and/or supraclavicular lymph nodes.
Treatment modalities in the GLOT PC 86/01 study
Patients included in the phase II study were treated as previously reported [8, 9] . Briefly, induction chemotherapy (DEI) consisted of a combination of doxorubicin 50 mg/m 2 on day 1, etoposide 150 mg/m 2 on days 1 and 2, ifosfamide 2 g/m 2 using a short two-hour infusion on days 1 and 2, and intravenous mesna 30 min before (2 g) and four and eight hours after (1 g) ifosfamide infusion, repeated every 21 days. For patients with limited disease, the treatment consisted of four courses of induction chemotherapy, followed by three courses of modified chemotherapy, alternated with radiotherapy given twice a day at a total dose of 51 Gy, and completed by two cycles of the initial chemotherapy. Patients with extensive disease received six additional cycles of DEI for a total of 10 courses.
Assessment of treatment efficacy and toxicity in the GLOT PC 86/01 study
Assessment of the initial response of all patients included in the trial was performed two weeks after the fourth chemotherapy course. The restaging procedures included a chest radiograph, a CT scan of the chest and a fiberoptic bronchoscopy with biopsies and cytology of bronchial aspirates. In addition, any test with initially positive results had to be repeated at this time. Complete response was defined as a complete regression of the primary tumor, including normalization of bronchoscopic abnormalities. Partial response was defined as a > 50% overall regression of the tumor, or a complete clinical regression with persistence of positive bronchial cytology or biopsy results. Objective response was defined by either complete or partial response. All tumor response evaluations were confirmed by an independant review committee. Early death was defined by less than two months' survival. Toxicity was evaluated using the World Health Organisation's criteria.
Statistical analysis
All registered patients were included in the statistical analysis. Comparisons were calculated using the chi-squared test for qualitative values, and the Student's /-test for quantitative values. Overall survival curves were calculated using the Kaplan-Meier method [12] . The endpoints were the date of the first course of chemotherapy, and the date of death or relapse or the last date of follow-up in surviving patients. Prognostic factors were determined using the log rank test for univariate analysis and the Cox model for multivariate analysis [13] . Results were considered significant for /"-values less than 0.05.
Results
Characteristics of the population of non-included patients
Patient characteristics
Of 178 consecutive patients with SCLC who were referred to our institution during the study period, 57 (31%) were not included in the on-going trials. We studied the clinical characteristics of this subpopulation of excluded patients and the reasons for their nonparticipation in the protocols. This group consisted of 48 males and 9 females, with a mean age of 67 ± 8 years (range 41-88). The age was significantly higher in the female population (73 vs. 65, P = 0.02). Twenty-eight percent of the patients had histories of severe coronary or peripheral artery disease.
Reasons for non-participation
Patients who were not included in clinical trials either (i) met ineligibility criteria, or (ii) were eligible but refused to participate or were not asked to enroll. As shown in Table 3 , 53 patients (93% of non-participants) were considered ineligible. Four patients were eligible but refused to enter the study (n = 2), or were not asked to participate (« = 2, mainly because they were members of the family of a physician). Given this low fraction of eligible patients among the non-participants, the likelihood of significant selection biases in the three clinical trials was low. Of the 53 ineligible patients, 18 (31.5 %) had multiple reasons for non-enrollment in the study. Long-term medical follow-up was considered non-feasible for 12 patients: 7 lived too far from our institution and 5 were unable to understand the treatment protocol and to follow the precise schedules. The sites of the previous tumor of the 8 patients who could not be included because of a history of cancer were head and neck (n -2), bladder (n -2), non-SCLC (n = 1), prostate (« = 1), central nervous system (n = 1) and breast (« = 1).
Staging procedures
For the 57 non-included patients, the staging procedures were left to the discretion of the physician whereas they were mandatory in the clinical trials. Patients not included in the protocols underwent only a fraction of the procedures for initial staging and response assessment (data not shown). Overall, only 18 (31%) patients underwent all listed staging procedures. According to the staging definition used by our group (see above), 43 (75%) non-participating patients were considered to have extensive disease.
Treatment modalities
Similarly, the treatment modalities for non-included patients were left to the discretion of the physician. Seven patients received only symptomatic treatment. One patient with limited disease received only chest radiotherapy. Chemotherapy was given to 49 (86%) of the patients as an initial treatment, and was followed by brain or chest radiotherapy in 32% of these patients. The Table 3 . Reasons for non-inclusion.
Reasons
Patients not Patients not included in the included in the three studies GLOT PC 86/ (n = 57) 01 only (n = 37)
Ineligibility criteria
The numbers in parentheses refer to the numbers of patients presenting each criteria as the only reason for non-inclusion. chemotherapy regimens included (1) the above-described DEI combination; (2) 
Treatment results
Response to therapy was assessed for 42 of the 50 treated patients. Objective tumor regression was described in 18 patients (36%). Forty-five patients died as a result of cancer progression, five of drug-related toxicity, and five of various complications apparently unrelated to treatment (three of cerebral stroke, one of gastro-intestinal hemorrhage and one of peritonitis). None of the nine patients excluded because of previous history of cancer showed evidence of progression of any neoplastic disease other than SCLC. The average survival time in this population was six months. The prognostic factors that significantly affected survival were a Karnofsky index lower than 50% (P -0.002), age greater than or equal to 70 years (P -0.02), and the presence of metastasis in the central nervous system (P -0.01). Objective response to therapy (P -0.016) and exclusion from the study only for geographical reasons (P -0.034) were associated with a better outcome. Neither weight loss, disease stage, nor any other category of the exclusion criteria had a statistically significant impact on survival.
Comparative analysis of included and non-included patients
Patient characteristics
To further characterize the subpopulation of non-participants, we compared the pre-treatment characteristics of the 73 patients included in the GLOT PC 86/01 trial to those of the 37 patients considered ineligible for this trial during the same period. The causes of exclusion of these 37 patients were representative of those of the overall population of excluded patients. As shown in Table 4 , patients not included in the phase II study had a significantly lower Karnofsky index and were older than included patients. Hemoptysis was more frequent in the included than in the excluded patients, whereas other symptoms did not differ significantly between the two groups.
Pre-treatment staging
Since disease stage is a major prognostic factor in patients with SCLC, we compared the results of the pretreatment staging procedures performed in included and excluded patients. Extensive disease was significantly more frequent in excluded patients than in patients included in the GLOT PC 86/01 trial (Table 5) . Cerebral metastases were more common in non-enrolled patients, while no difference was found for the other sites of metastasis.
Treatment modalities and results
Of the 37 excluded patients, 16 (43%) were offered DEI chemotherapy, the treatment given in the on-going GLOT PC 86/01 trial. The toxic effects of the treatment were not worse in these 16 patients than in patients included in the GLOT PC 86/01 trial (i.e., 12% vs. 14% of grade IV hematologic toxicity, P > 0.05). As shown in Table 6 , the objective response rate was significantly lower in the excluded patients (40%), than in patients included in the phase II study (78%). Non-enrolled patients had worse prognoses, as shown by a lower survival rate (Table 6 and Figure 1 ). The causes of death were similar in the two groups, with the majority of the patients dying of cancer progression. However, early Months from diagnosis Figure 1 . Survival of patients with small-cell lung cancer who were included or not included in the protocols.
death from progressive disease was observed in 11 nonenrolled patients (29%) but none of the included patients (P < 0.001).
Analysis of prognostic factors
Based on the worse prognosis for non-participating patients, we next questioned whether predictive factors for survival could be identified in excluded patients by univariate and multivariate analysis. Based on the univariate analysis performed on the overall population of 110 patients, the statistically significant predictive factors for survival were a Karnofsky index of less than 50% (P = 0.0007), age greater than 70 years (P = 0.013), extensive disease (P = 0.00012), the presence of bone marrow metastasis (P = 0.0014) and exclusion from the study (P -0.01). However, by multivariate analysis, only disease stage and bone marrow metastasis were significant. Since data on the latter parameter were missing for many of the non-included patients (data not shown), we also performed the multivariate analysis without taking it into account. Disease stage, Karnofsky index and age remained statistically significant independent factors. Interestingly, exclusion from the protocol was not an independent prognostic factor by multivariate analysis.
Discussion
Only a small fraction of patients with SCLC are included in clinical trials, raising the concern that included patients may not be representative of the patient population as a whole. Moreover, little is known about the subpopulation of patients who are not included in clinical trials. In this study we report the clinical characteristics, treatment modalities, and evolution of a cohort of patients referred to our institution for SCLC, but who were not included in three different consecutive clinical trials [8] [9] [10] [11] . All but two patients who were eligible were given the opportunity to enter a clinical trial, and the majority of patients offered participation enrolled in one of the studies. Thus, the percentage of included patients among eligible patients was very high, and the risk of selection biases in these three trials was low [2] . The accrual level of patients in clinical trials is usually determined by treatment-related factors, and by the study design [14] . It may also be influenced, to a lesser extent, by other factors such as age, gender, and occupational status [3, 5, 14, 15] . The high rate of participation may reflect the non-randomized design of all three trials. Moreover, French law required only oral consent for participation at the time of the first study. Full informed and written consent has been shown to decrease patient participation, especially when the treatment is randomly allocated [14, [16] [17] [18] [19] . Two patients were not asked to participate because 'they belonged to the family of a physician'; this clearly illustrates the reluctance of physicians (or their relatives) to take part in clinical trials, as well as physicians' concern of a possible negative impact of enrollment in a trial on doctor-patient relationships [17] .
However, of 178 patients with SCLC who were referred to our center during the study period, almost onethird were ineligible for the ongoing clinical trials. Since various exclusion criteria were noted, this population of ineligible patients may be expected to be heterogeneous. A majority of patients were excluded for medical reasons such as low Karnofsky index, advanced age, or contraindication for the use of anthracyclines. Some biological criteria (such as abnormal prothrombin time) were always associated with at least one other major exclusion criteria, and were therefore irrelevant to the selection of high-risk patients. Previous history of cancer is usually considered a pertinent exclusion criterion because of a theoretical risk of death due to a different neoplastic disease than SCLC. However, since none of these cancers progressed, they also did not interfere with the assessment of the SCLC treatment efficacy. This implies that patients who are disease-free for at least five years after treatment could be included in future studies. On the other hand, 28% of the non-included patients had histories of atherosclerosis, and three died of cerebral stroke, confirming that a careful examination of cardiovascular tobacco-related diseases should be performed, although this is not a recognized prognostic factor in patients with SCLC [20] .
Of particular interest is the high proportion of patients whose only ineligibility criterion was advanced age. The underrepresentation of elderly patients in cancer treatment protocols has previously been reported [15] , so that the available information on the efficacy of cancer treatments may be irrelevant for the majority of elderly patients. The age range considered acceptable for participation in cancer clinical trials should be extended whenever possible, or specific protocols should be designed to better assess treatment results and tolerance in elderly patients [15, 21] .
The 'non-feasibility of a long-term follow-up' was the most common of the non-medical reasons for ineligibility. Determining the ability of a given patient to understand the objectives and schedules of the treatment is difficult and very subjective. Negrier et al. [22] showed in a study of 24 patient-candidates for an anticancer immunotherapy trial, that although most patients correctly understood the information given to them prior to enrollment, two-thirds of them later requested additional information. However, these patients were referred by their physicians as potential participants in clinical trials and may not reflect the affected population as a whole. Moreover, the amount of information that patients require and the degree to which they want to participate in their own medical management is highly variable from one patient to another. For instance, older patients prefer a non-participatory patient role [23] .
Staging procedures were not extensively performed in patients who were not included in clinical trials. A series of procedures is usually recommended in SCLC treatment protocols; however, in the non-protocol setting, once a site of metastatic disease has been identified, extensive radiologic investigations may not be considered necessary [24, 25] . Moreover, we previously demonstrated in the group of patients included in the GLOT PC 86/01 protocol, that a step-by-step use of simple clinical and biological tests can approximate the probability of metastatic SCLC, so that it may be possible to avoid some aggressive staging procedures outside clinical trials [26] .
The prognostic factors for survival in the non-included population were consistent with published data [6, 20, [27] [28] [29] [30] [31] [32] , apart from the non-significance of female gender. Not surprisingly, patients excluded only for non-medical reasons such as geographical contraints had better outcomes than the other excluded patients.
Comparative analysis between patients included and not included in clinical trials has rarely been reported [7] . We chose to perform this comparison only in the patients who were ineligible for the largest of our clinical trials (GLOT PC 86/01) [8, 9] , because ineligibility criteria differed from one trial to the other, and because sufficient detailed data for the AR 88/01 trial were not available. Non-enrolled patients had a significantly lower Karnofsky index and were older than their counterparts included in the trial, a finding directly related to the definition of the ineligibility criteria. The higher incidence of hemoptysis in included patients may be a consequence of early detection of the cancer in patients with hemoptysis, who thus have a better general status and a higher likelihood of inclusion in a clinical trial. Ineligible patients presented more frequently with metastatic disease, although fewer extensive staging procedures were performed in these patients. Consistent with the higher incidence of metastasis, response to treatment was poor, and the response rate of 40% may be overestimated because of inadequate staging reassessment. Thus, this study demonstrates that non-participating patients differed notably from patients included in the trials.
The different results seen between included and excluded patients may have several explanations, such as differences in (a) initial characteristics influencing the prognosis, (b) diagnostic procedures performed, (c) treatment regimens, or (d) the effect of being enrolled in a treatment protocol. Although we cannot rule out the possibility that the difference in outcome of non-enrolled patients may be partially due to less optimal treatment schedules or dosages, based on our findings it is more likely related to their initial characteristics. Also, the multivariate analysis clearly showed that the ineligibility for clinical trials was not an independant predictive factor for survival. Although our study was not designed to assess this particular point, our results are in contrast to those of Karjalainen and Palva [33] , who showed in a large non-randomized comparative study, that being enrolled in a treatment protocol improved the survival of patients with multiple myeloma.
Taken together, these findings demonstrate that the clinical characteristics of the patients included in our trials differed from those of the overall population of patients treated for SCLC. Since the percentage of included patients among eligible patients was high, this difference was more likely due to restrictive eligibility criteria than to patient or physician biases. Based on the lack of representativeness of the subgroup of included patients, caution should be used in applying data to the overall population and in defining treatment guidelines. As a simple measure to insure that the published results are fully interpretable, we suggest that the rate and major characteristics of ineligible and non-participating patients be mentioned in any publication of a clinical oncology trial.
